Christian Hagel1, Rolf Buslei2, Michael Buchfelder3, Rudolf Fahlbusch4, Markus Bergmann5, Armin Giese6, Jörg Flitsch7, Dieter K Lüdecke7, Markus Glatzel1, Wolfgang Saeger8. 1. Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. 2. Department of Neuropathology, Friedrich-Alexander University Erlangen-Nürnberg, Schwabachanlage 6, 91054, Erlangen, Germany. 3. Neurochirurgische Klinik, Universitätsklinikum Erlangen, Schwabachanlage 6, 91054, Erlangen, Germany. 4. International Neuroscience Institute (INI), Rudolf-Pichelmayr-Str. 4, 30625, Hannover, Germany. 5. Klinikum Bremen-Mitte, Zentrum für Pathologie, Institut für klinische Neuropathologie, St.-Jürgen-Str. 1, 28177, Bremen, Germany. 6. Zentrum für Neuropathologie und Prionforschung, Ludwig-Maximilians-Universität München, Feodor-Lynen-Str. 23, 81377, Munich, Germany. 7. Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. 8. Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. w.saeger@uke.de.
Abstract
PURPOSE: To analyse the antigen expression profiles of 27 cases of pituicytoma, spindle cell oncocytoma, and granular cell tumour of the sellar region concerning a common pituicytic origin of neoplastic cells. METHODS: Material from 12 female and 15 male patients (13 granular cell tumours of the sellar region, 10 pituicytomas, four spindle cell oncocytomas) collected in the German Registry of Pituitary Tumours between 1993 and 2015 was re-evaluated according to the current WHO classification of tumours of the central nervous system and supplementary immunohistochemistry including S100-protein, CD56, CD68, thyroid transcription factor-1 (TTF-1), and Ki-67 was performed. RESULTS: S100-protein was detected in all 27 tumours and TTF-1 in all 16 tumours that were assessed. Vimentin was expressed in all 13 cases investigated whereas broad spectrum cytokeratin was not detected in any of 14 evaluated cases. GFAP was observed in nine out of 21 cases. 15 out of 17 investigated lesions showed some CD68 expression and five out of 14 cases were labelled with CD56 antibodies. Proliferative activity did not differ significantly between the three tumour subgroups although one primary and one recurrent pituicytoma showed exceptionally high Ki-67-proliferation indices of 15.3 and 12.7 %, respectively (means: granular cell tumour of the sellar region 2.0 %, pituicytoma 2.8 %, spindle cell oncocytoma 2.7 %). CONCLUSIONS: The study confirms and expands earlier data and is in line with the notion that the three tumour types are variants of pituicytoma.
PURPOSE: To analyse the antigen expression profiles of 27 cases of pituicytoma, spindle cell oncocytoma, and granular cell tumour of the sellar region concerning a common pituicytic origin of neoplastic cells. METHODS: Material from 12 female and 15 male patients (13 granular cell tumours of the sellar region, 10 pituicytomas, four spindle cell oncocytomas) collected in the German Registry of Pituitary Tumours between 1993 and 2015 was re-evaluated according to the current WHO classification of tumours of the central nervous system and supplementary immunohistochemistry including S100-protein, CD56, CD68, thyroid transcription factor-1 (TTF-1), and Ki-67 was performed. RESULTS: S100-protein was detected in all 27 tumours and TTF-1 in all 16 tumours that were assessed. Vimentin was expressed in all 13 cases investigated whereas broad spectrum cytokeratin was not detected in any of 14 evaluated cases. GFAP was observed in nine out of 21 cases. 15 out of 17 investigated lesions showed some CD68 expression and five out of 14 cases were labelled with CD56 antibodies. Proliferative activity did not differ significantly between the three tumour subgroups although one primary and one recurrent pituicytoma showed exceptionally high Ki-67-proliferation indices of 15.3 and 12.7 %, respectively (means: granular cell tumour of the sellar region 2.0 %, pituicytoma 2.8 %, spindle cell oncocytoma 2.7 %). CONCLUSIONS: The study confirms and expands earlier data and is in line with the notion that the three tumour types are variants of pituicytoma.
Authors: Simona Gurzu; Diana Ciortea; Adrian Tamasi; Mircea Golea; Andrea Bodi; Danut Ioan Sahlean; Attila Kovecsi; Ioan Jung Journal: Arch Dermatol Res Date: 2014-09-28 Impact factor: 3.017
Authors: Klaus Christian Mende; Jakob Matschke; Till Burkhardt; Wolfgang Saeger; Rolf Buslei; Michael Buchfelder; Rudolf Fahlbusch; Manfred Westphal; Jörg Flitsch Journal: CNS Neurosci Ther Date: 2017-05-28 Impact factor: 5.243
Authors: Abdul-Kareem Ahmed; Hassan Y Dawood; David J Cote; Tejus A Bale; Umberto De Girolami; Edward R Laws; Timothy R Smith Journal: Pituitary Date: 2019-12 Impact factor: 4.107
Authors: Angela N Viaene; Edward B Lee; Jason N Rosenbaum; Ilya M Nasrallah; MacLean P Nasrallah Journal: Acta Neuropathol Commun Date: 2019-05-02 Impact factor: 7.801